Modulating acute neuroinflammation in intracerebral hemorrhage: the potential promise of currently approved medications for multiple sclerosis

References

• Larsen GL, Henson PM. Mediators of inflammation. Annu Rev Immunol. 1983;1:335–359.
   PubMed Web of Science ®Google Scholar
• Mozaffarian D, Benjamin EJ, Go AS, et al. Heart disease and stroke statistics-2016 update: a report from the American Heart Association. Circulation. 2016;133:e38–e360.
   PubMed Web of Science ®Google Scholar
• Hammond MD, Taylor RA, Mullen MT, et al. CCR2+ Ly6C(hi) inflammatory monocyte recruitment exacerbates acute disability following intracerebral hemorrhage. J Neurosci. 2014;34:3901–3909.
   PubMed Web of Science ®Google Scholar
• Wang J. Preclinical and clinical research on inflammation after intracerebral hemorrhage. Prog Neurobiol. 2010;92:463–477.
   PubMed Web of Science ®Google Scholar
• Wang J, Doré S. Inflammation after intracerebral hemorrhage. J Cereb Blood Flow Metab. 2007;27:894–908.
   PubMed Web of Science ®Google Scholar
• Carmichael ST, Vespa PM, Saver JL, et al. Genomic profiles of damage and protection in human intracerebral hemorrhage. J Cereb Blood Flow Metab. 2008;28:1860–1875.
   PubMed Web of Science ®Google Scholar
• Adeoye O, Walsh K, Woo JG, et al. Peripheral monocyte count is associated with case fatality after intracerebral hemorrhage. J Stroke Cerebrovasc Dis. 2014;23:e107–e111.
   PubMed Web of Science ®Google Scholar
• Hammond MD, Ambler WG, Ai Y, et al. α4 integrin is a regulator of leukocyte recruitment after experimental intracerebral hemorrhage. Stroke. 2014;45:2485–2487.
   PubMed Web of Science ®Google Scholar
• Walsh KB, Sekar P, Langefeld CD, et al. Monocyte count and 30-day case fatality in intracerebral hemorrhage. Stroke. 2015;46:2302–2304.
   PubMedGoogle Scholar
• Rolland WB 2nd, Manaenko A, Lekic T, et al. FTY720 is neuroprotective and improves functional outcomes after intracerebral hemorrhage in mice. Acta Neurochir Suppl. 2011;111:213–217.
   PubMedGoogle Scholar
• Zhong Q, Zhou K, Liang Q, et al. Interleukin‐23 secreted by activated macrophages drives γδT cell production of interleukin‐17 to aggravate secondary injury after intracerebral hemorrhage. J Am Heart Assoc. 2016;5. Available from: doi: 10.1161/jaha.116.004340.
   Web of Science ®Google Scholar
• Hauser SL, Oksenberg JR. The neurobiology of multiple sclerosis: genes, inflammation, and neurodegeneration. Neuron. 2006;52:61–76.
   PubMed Web of Science ®Google Scholar
• van der Zwan M, Baan CC, van Gelder T, et al. Review of the clinical pharmacokinetics and pharmacodynamics of alemtuzumab and its use in kidney transplantation. Clin Pharmacokinet. 2017;57(2):191–207.
   Web of Science ®Google Scholar
• Pasadhika S, Rosenbaum JT. Update on the use of systemic biologic agents in the treatment of noninfectious uveitis. Biologics. 2014;8:67–81.
   PubMedGoogle Scholar
• Rodrigues EB, Farah ME, Maia M, et al. Therapeutic monoclonal antibodies in ophthalmology. Prog Retin Eye Res. 2009;28:117–144.
   PubMed Web of Science ®Google Scholar
• Rose JW, Watt HE, White AT, et al. Treatment of multiple sclerosis with an anti-interleukin-2 receptor monoclonal antibody. Ann Neurol. 2004;56:864–867.
   PubMed Web of Science ®Google Scholar
• Wolinsky JS, Narayana PA, O’Connor P, et al. Glatiramer acetate in primary progressive multiple sclerosis: results of a multinational, multicenter, double-blind, placebo-controlled trial. Ann Neurol. 2007;61:14–24.
   PubMed Web of Science ®Google Scholar
• Nikfar S, Rahimi R, Abdollahi M. A meta-analysis of the efficacy and tolerability of interferon-β in multiple sclerosis, overall and by drug and disease type. Clin Ther. 2010;32:1871–1888.
   PubMed Web of Science ®Google Scholar
• Smith DI, Swamy PM, Heffernan MP. Off-label uses of biologics in dermatology: interferon and intravenous immunoglobulin (part 1 of 2). J Am Acad Dermatol. 2007;56:e1–e54.
   PubMedGoogle Scholar
• Grey Née Cotte S, Salmen Née Stroet A, von Ahsen N, et al. Lack of efficacy of mitoxantrone in primary progressive multiple sclerosis irrespective of pharmacogenetic factors: a multi-center, retrospective analysis. J Neuroimmunol. 2015;278:277–279.
   PubMed Web of Science ®Google Scholar
• Vacchelli E, Aranda F, Eggermont A, et al. Trial watch: chemotherapy with immunogenic cell death inducers. Oncoimmunology. 2014;3:e27878.
   PubMed Web of Science ®Google Scholar
• Sellebjerg F, Cadavid D, Steiner D, et al. Exploring potential mechanisms of action of natalizumab in secondary progressive multiple sclerosis. Ther Adv Neurol Disord. 2016;9:31–43.
   PubMed Web of Science ®Google Scholar
• He D, Guo R, Zhang F, et al. Rituximab for relapsing-remitting multiple sclerosis. Cochrane Database Syst Rev. 2013;6(12):CD009130. doi: 10.1002/14651858.
   Google Scholar
• Graves JE, Nunley K, Heffernan MP. Off-label uses of biologics in dermatology: rituximab, omalizumab, infliximab, etanercept, adalimumab, efalizumab, and alefacept (part 2 of 2). J Am Acad Dermatol. 2007;56:e55–e79.
   PubMedGoogle Scholar
• Rao SP, Sancho J, Campos-Rivera J, et al. Human peripheral blood mononuclear cells exhibit heterogeneous CD52 expression levels and show differential sensitivity to alemtuzumab mediated cytolysis. PLoS One. 2012;7:e39416.
   PubMed Web of Science ®Google Scholar
• Hu Y, Turner MJ, Shields J, et al. Investigation of the mechanism of action of alemtuzumab in a human CD52 transgenic mouse model. Immunology. 2009;128:260–270.
   PubMed Web of Science ®Google Scholar
• Zhang X, Tao Y, Chopra M, et al. Differential reconstitution of T cell subsets following immunodepleting treatment with alemtuzumab (anti-CD52 monoclonal antibody) in patients with relapsing-remitting multiple sclerosis. J Immunol. 2013;191:5867–5874.
   PubMed Web of Science ®Google Scholar
• Havari E, Turner MJ, Campos-Rivera J, et al. Impact of alemtuzumab treatment on the survival and function of human regulatory T cells in vitro. Immunology. 2013;141:123–131.
   Web of Science ®Google Scholar
• Wuest SC, Edwan JH, Martin JF, et al. A role for interleukin-2 trans-presentation in dendritic cell–mediated T cell activation in humans, as revealed by daclizumab therapy. Nat Med. 2011;17:604–609.
   PubMed Web of Science ®Google Scholar
• Lin YC, Winokur P, Blake A, et al. Daclizumab reverses intrathecal immune cell abnormalities in multiple sclerosis. Ann Clin Transl Neurol. 2015;2:445–455.
   PubMed Web of Science ®Google Scholar
• Schulze-Topphoff U, Varrin-Doyer M, Pekarek K, et al. Dimethyl fumarate treatment induces adaptive and innate immune modulation independent of Nrf2. Proc Natl Acad Sci USA. 2016;113:4777–4782.
   PubMed Web of Science ®Google Scholar
• Lehmann JCU, Listopad JJ, Rentzsch CU, et al. Dimethylfumarate induces immunosuppression via glutathione depletion and subsequent induction of heme oxygenase 1. J Invest Dermatol. 2007;127:835–845.
   PubMed Web of Science ®Google Scholar
• Longbrake EE, Ramsbottom MJ, Cantoni C, et al. Dimethyl fumarate selectively reduces memory T cells in multiple sclerosis patients. Mult Scler. 2016;22:1061–1070.
   PubMed Web of Science ®Google Scholar
• Peng H, Guerau-de-Arellano M, Mehta VB, et al. Dimethyl fumarate inhibits dendritic cell maturation via nuclear factor κB (NF-κB) and extracellular signal-regulated kinase 1 and 2 (ERK1/2) and mitogen stress-activated kinase 1 (MSK1) signaling. J Biol Chem. 2012;287:28017–28026.
   PubMed Web of Science ®Google Scholar
• Ockenfels HM, Schultewolter T, Ockenfels G, et al. The antipsoriatic agent dimethylfumarate immunomodulates T-cell cytokine secretion and inhibits cytokines of the psoriatic cytokine network. Br J Dermatol. 1998;139:390–395.
   PubMed Web of Science ®Google Scholar
• Stoof TJ, Flier J, Sampat S, et al. The antipsoriatic drug dimethylfumarate strongly suppresses chemokine production in human keratinocytes and peripheral blood mononuclear cells. Br J Dermatol. 2001;144:1114–1120.
   PubMed Web of Science ®Google Scholar
• Kowarik MC, Pellkofer HL, Cepok S, et al. Differential effects of fingolimod (FTY720) on immune cells in the CSF and blood of patients with MS. Neurology. 2011;76:1214–1221.
   PubMed Web of Science ®Google Scholar
• Luessi F, Kraus S, Trinschek B, et al. FTY720 (fingolimod) treatment tips the balance towards less immunogenic antigen-presenting cells in patients with multiple sclerosis. Mult Scler. 2015;21:1811–1822.
   PubMed Web of Science ®Google Scholar
• Thomas K, Sehr T, Proschmann U, et al. Fingolimod additionally acts as immunomodulator focused on the innate immune system beyond its prominent effects on lymphocyte recirculation. J Neuroinflammation. 2017;14:41.
   PubMed Web of Science ®Google Scholar
• Gao C, Qian Y, Huang J, et al. A Three-Day Consecutive Fingolimod Administration Improves Neurological Functions and Modulates Multiple Immune Responses of CCI Mice. Mol Neurobiol. 2017;54:8348–8360.
   PubMed Web of Science ®Google Scholar
• Müller H, Hofer S, Kaneider N, et al. The immunomodulator FTY720 interferes with effector functions of human monocyte-derived dendritic cells. Eur J Immunol. 2005;35:533–545.
   PubMed Web of Science ®Google Scholar
• Grützke B, Hucke S, Gross CC, et al. Fingolimod treatment promotes regulatory phenotype and function of B cells. Ann Clin Transl Neurol. 2015;2:119–130.
   PubMed Web of Science ®Google Scholar
• Blumenfeld S, Staun-Ram E, Miller A. Fingolimod therapy modulates circulating B cell composition, increases B regulatory subsets and production of IL-10 and TGFβ in patients with multiple sclerosis. J Autoimmun. 2016;70:40–51.
   PubMed Web of Science ®Google Scholar
• Kim HJ, Ifergan I, Antel JP, et al. Type 2 monocyte and microglia differentiation mediated by glatiramer acetate therapy in patients with multiple sclerosis. J Immunol. 2004;172:7144–7153.
   PubMed Web of Science ®Google Scholar
• Weber MS, Starck M, Wagenpfeil S, et al. Multiple sclerosis: glatiramer acetate inhibits monocyte reactivity in vitro and in vivo. Brain. 2004;127:1370–1378.
   PubMed Web of Science ®Google Scholar
• Toker A, Slaney CY, Bäckström BT, et al. Glatiramer acetate treatment directly targets CD11b(+)Ly6G(-) monocytes and enhances the suppression of autoreactive T cells in experimental autoimmune encephalomyelitis. Scand J Immunol. 2011;74:235–243.
   PubMed Web of Science ®Google Scholar
• Weber MS, Prod’homme T, Youssef S, et al. Type II monocytes modulate T cell–mediated central nervous system autoimmune disease. Nat Med. 2007;13:935–943.
   PubMed Web of Science ®Google Scholar
• Spadaro M, Montarolo F, Perga S, et al. Biological activity of glatiramer acetate on Treg and anti-inflammatory monocytes persists for more than 10years in responder multiple sclerosis patients. Clin Immunol. 2017;181:83–88.
   PubMed Web of Science ®Google Scholar
• Burger D, Molnarfi N, Weber MS, et al. Glatiramer acetate increases IL-1 receptor antagonist but decreases T cell-induced IL-1 in human monocytes and multiple sclerosis. Proc Nat Acad Sci. 2009;106:4355–4359.
   PubMed Web of Science ®Google Scholar
• Duda PW, Schmied MC, Cook SL, et al. Glatiramer acetate (Copaxone®) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis. J Clin Invest. 2000;105:967–976.
   PubMed Web of Science ®Google Scholar
• Gran B, Tranquill LR, Chen M, et al. Mechanisms of immunomodulation by glatiramer acetate. Neurology. 2000;55:1704–1714.
   PubMed Web of Science ®Google Scholar
• Chen L, Yao Y, Wei C, et al. T cell immunity to glatiramer acetate ameliorates cognitive deficits induced by chronic cerebral hypoperfusion by modulating the microenvironment. Sci Rep. 2015;5:14308.
   PubMed Web of Science ®Google Scholar
• Sanna A, Fois ML, Arru G, et al. Glatiramer acetate reduces lymphocyte proliferation and enhances IL-5 and IL-13 production through modulation of monocyte-derived dendritic cells in multiple sclerosis. Clin Exp Immunol. 2006;143:357–362.
   PubMed Web of Science ®Google Scholar
• Oreja-Guevara C, Ramos-Cejudo J, Aroeira LS, et al. TH1/TH2 Cytokine profile in relapsing-remitting multiple sclerosis patients treated with Glatiramer acetate or Natalizumab. BMC Neurol. 2012;18:12–95.
   Google Scholar
• Aharoni R, Eilam R, Stock A, et al. Glatiramer acetate reduces Th-17 inflammation and induces regulatory T-cells in the CNS of mice with relapsing–remitting or chronic EAE. J Neuroimmunol. 2010;225:100–111.
   PubMed Web of Science ®Google Scholar
• Ireland SJ, Guzman AA, O’Brien DE, et al. The effect of glatiramer acetate therapy on functional properties of B cells from patients with relapsing-remitting multiple sclerosis. JAMA Neurol. 2014;71:1421–1428.
   PubMed Web of Science ®Google Scholar
• Ziemssen T, Kümpfel T, Klinkert WEF, et al. Glatiramer acetate-specific T-helper 1- and 2-type cell lines produce BDNF: implications for multiple sclerosis therapy. Brain-derived neurotrophic factor. Brain. 2002;125:2381–2391.
   PubMed Web of Science ®Google Scholar
• Aharoni R, Eilam R, Domev H, et al. The immunomodulator glatiramer acetate augments the expression of neurotrophic factors in brains of experimental autoimmune encephalomyelitis mice. Proc Natl Acad Sci USA. 2005;102:19045–19050.
   PubMed Web of Science ®Google Scholar
• Azoulay D, Vachapova V, Shihman B, et al. Lower brain-derived neurotrophic factor in serum of relapsing remitting MS: reversal by glatiramer acetate. J Neuroimmunol. 2005;167:215–218.
   PubMed Web of Science ®Google Scholar
• Skihar V, Silva C, Chojnacki A, et al. Promoting oligodendrogenesis and myelin repair using the multiple sclerosis medication glatiramer acetate. Proc Natl Acad Sci USA. 2009;106:17992–17997.
   PubMed Web of Science ®Google Scholar
• Johnson KP, Brooks BR, Cohen JA, et al. Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Copolymer 1 Multiple Sclerosis Study Group. Neurology. 1998;50:701–708.
   PubMed Web of Science ®Google Scholar
• Runkel L, Meier W, Pepinsky RB, et al. Structural and functional differences between glycosylated and non-glycosylated forms of human interferon-beta (IFN-beta). Pharm Res. 1998;15:641–649.
   PubMed Web of Science ®Google Scholar
• Liu Z, Pelfrey CM, Cotleur A, et al. Immunomodulatory effects of interferon beta-1a in multiple sclerosis. J Neuroimmunol. 2001;112:153–162.
   PubMed Web of Science ®Google Scholar
• Kantor AB, Deng J, Waubant E, et al. Identification of short-term pharmacodynamic effects of interferon-beta-1a in multiple sclerosis subjects with broad- based phenotypic profiling. J Neuroimmunol. 2007;188:103–116.
   PubMed Web of Science ®Google Scholar
• Shapiro S, Galboiz Y, Lahat N, et al. The “immunological-synapse” at its APC side in relapsing and secondary-progressive multiple sclerosis: modulation by interferon-beta. J Neuroimmunol. 2003;144:116–124.
   PubMed Web of Science ®Google Scholar
• Zhang X, Jin J, Tang Y, et al. IFN-beta1a inhibits the secretion of Th17-polarizing cytokines in human dendritic cells via TLR7 up-regulation. J Immunol. 2009;182:3928–3936.
   PubMed Web of Science ®Google Scholar
• Zang YCQ, Skinner SM, Robinson RR, et al. Regulation of differentiation and functional properties of monocytes and monocyte-derived dendritic cells by interferon beta in multiple sclerosis. Mult Scler. 2004;10:499–506.
   PubMed Web of Science ®Google Scholar
• Azoulay D, Mausner-Fainberg K, Urshansky N, et al. Interferon-beta therapy up-regulates BDNF secretion from PBMCs of MS patients through a CD40-dependent mechanism. J Neuroimmunol. 2009;211:114–119.
   PubMed Web of Science ®Google Scholar
• Lund BT, Ashikian N, Ta HQ, et al. Increased CXCL8 (IL-8) expression in multiple sclerosis. J Neuroimmunol. 2004;155:161–171.
   PubMed Web of Science ®Google Scholar
• Berghella AM, Totaro R, Pellegrini P, et al. Immunological study of IFNbeta-1a-treated and untreated multiple sclerosis patients: clarifying IFNbeta mechanisms and establishing specific dendritic cell immunotherapy. Neuroimmunomodulation. 2005;12:29–44.
   PubMed Web of Science ®Google Scholar
• Mukaida N, Harada A, Matsushima K. Interleukin-8 (IL-8) and monocyte chemotactic and activating factor (MCAF/MCP-1), chemokines essentially involved in inflammatory and immune reactions. Cytokine Growth Factor Rev. 1998;9:9–23.
   PubMed Web of Science ®Google Scholar
• Lucas M, Sánchez-Soliño O, Solano F, et al. Interferon beta-1b inhibits reactive oxygen species production in peripheral blood monocytes of patients with relapsing-remitting multiple sclerosis. Neurochem Int. 1998;33:101–102.
   PubMed Web of Science ®Google Scholar
• Boylan MT, Crockard AD, Duddy ME, et al. Interferon-beta1a administration results in a transient increase of serum amyloid A protein and C-reactive protein: comparison with other markers of inflammation. Immunol Lett. 2001;75:191–197.
   PubMed Web of Science ®Google Scholar
• Kieseier BC. The mechanism of action of interferon-β in relapsing multiple sclerosis. CNS Drugs. 2011;25:491–502.
   PubMed Web of Science ®Google Scholar
• O’Toole D, Love WC. Interferon-β-1b and interferon-γ have similar inhibitory effects on apolipoprotein-E production in the monocyte/macrophage. Multiple Scler J. 2002;8:124–129.
   PubMedGoogle Scholar
• Iarlori C, Reale M, De Luca G, et al. Interferon beta-1b modulates MCP-1 expression and production in relapsing-remitting multiple sclerosis. J Neuroimmunol. 2002;123:170–179.
   PubMed Web of Science ®Google Scholar
• Wostradowski T, Gudi V, Pul R, et al. Effect of interferon-β1b on CXCR4-dependent chemotaxis in T cells from multiple sclerosis patients. Clin Exp Immunol. 2015;182:162–172.
   PubMed Web of Science ®Google Scholar
• Guillemin GJ, Kerr SJ, Pemberton LA, et al. IFN-beta1b induces kynurenine pathway metabolism in human macrophages: potential implications for multiple sclerosis treatment. J Interferon Cytokine Res. 2001;21:1097–1101.
   PubMed Web of Science ®Google Scholar
• Rinehart JJ, Young D, Laforge J, et al. Phase I/II trial of interferon-beta-serine in patients with renal cell carcinoma: immunological and biological effects. Cancer Res. 1987;47:2481–2485.
   PubMed Web of Science ®Google Scholar
• Maffione AB, Tatò E, Losito S, et al. In vivo effects of recombinant-interferon-beta1b treatment on polymorphonuclear cell and monocyte functions and on T-cell-mediated antibacterial activity in patients with relapsing-remitting multiple sclerosis. Immunopharmacol Immunotoxicol. 2000;22:1–18.
   PubMed Web of Science ®Google Scholar
• Jensen MA, Yanowitch RN, Reder AT, et al. Immunoglobulin-like transcript 3, an inhibitor of T cell activation, is reduced on blood monocytes during multiple sclerosis relapses and is induced by interferon beta-1b. Mult Scler. 2010;16:30–38.
   PubMedGoogle Scholar
• Genç K, Dona DL, Reder AT. Increased CD80(+) B cells in active multiple sclerosis and reversal by interferon beta-1b therapy. J Clin Invest. 1997;99:2664–2671.
   PubMed Web of Science ®Google Scholar
• Schiller JH, Storer B, Paulnock DM, et al. A direct comparison of biological response modulation and clinical side effects by interferon-beta ser, interferon-gamma, or the combination of interferons beta ser and gamma in humans. J Clin Invest. 1990;86:1211–1221.
   PubMed Web of Science ®Google Scholar
• Jalosinski M, Karolczak K, Mazurek A, et al. The effects of methylprednisolone and mitoxantrone on CCL5-induced migration of lymphocytes in multiple sclerosis. Acta Neurol Scand. 2008;118:120–125.
   PubMed Web of Science ®Google Scholar
• Kopadze T, Dehmel T, Hartung H-P, et al. Inhibition by mitoxantrone of in vitro migration of immunocompetent cells: a possible mechanism for therapeutic efficacy in the treatment of multiple sclerosis. Arch Neurol. 2006;63:1572–1578.
   PubMedGoogle Scholar
• Burns SA, Lee Archer R, Chavis JA, et al. Mitoxantrone repression of astrocyte activation: relevance to multiple sclerosis. Brain Res. 2012;1473:236–241.
   PubMed Web of Science ®Google Scholar
• Neuhaus O, Wiendl H, Kieseier BC, et al. Multiple sclerosis: Mitoxantrone promotes differential effects on immunocompetent cells in vitro. J Neuroimmunol. 2005;168:128–137.
   PubMed Web of Science ®Google Scholar
• Pelfrey CM, Cotleur AC, Zamor N, et al. Immunological studies of mitoxantrone in primary progressive MS. J Neuroimmunol. 2006;175:192–199.
   PubMed Web of Science ®Google Scholar
• Gbadamosi J, Buhmann C, Tessmer W, et al. Effects of mitoxantrone on multiple sclerosis patients’ lymphocyte subpopulations and production of immunoglobulin, TNF-alpha and IL-10. Eur Neurol. 2003;49:137–141.
   PubMed Web of Science ®Google Scholar
• Stüve O, Marra CM, Bar-Or A, et al. Altered CD4+/CD8+ T-cell ratios in cerebrospinal fluid of natalizumab-treated patients with multiple sclerosis. Arch Neurol. 2006;63:1383–1387.
   PubMed Web of Science ®Google Scholar
• Khademi M, Bornsen L, Rafatnia F, et al. The effects of natalizumab on inflammatory mediators in multiple sclerosis: prospects for treatment-sensitive biomarkers. Eur J Neurol. 2009;16:528–536.
   PubMed Web of Science ®Google Scholar
• Mellergård J, Edström M, Vrethem M, et al. Natalizumab treatment in multiple sclerosis: marked decline of chemokines and cytokines in cerebrospinal fluid. Mult Scler. 2010;16:208–217.
   PubMed Web of Science ®Google Scholar
• del Pilar Martin M, Cravens PD, Winger R, et al. Decrease in the numbers of dendritic cells and CD4+ T cells in cerebral perivascular spaces due to natalizumab. Arch Neurol. 2008;65:1596–1603.
   PubMed Web of Science ®Google Scholar
• Kappos L, Li D, Calabresi PA, et al. Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial. Lancet. 2011;378:1779–1787.
   PubMed Web of Science ®Google Scholar
• Bar-Or A, Fawaz L, Fan B, et al. Abnormal B-cell cytokine responses a trigger of T-cell-mediated disease in MS? Ann Neurol. 2010;67:452–461.
   PubMed Web of Science ®Google Scholar
• Palanichamy A, Jahn S, Nickles D, et al. Rituximab efficiently depletes increased CD20-expressing T cells in multiple sclerosis patients. J Immunol. 2014;193:580–586.
   PubMed Web of Science ®Google Scholar
• Lehmann-Horn K, Schleich E, Hertzenberg D, et al. Anti-CD20 B-cell depletion enhances monocyte reactivity in neuroimmunological disorders. J Neuroinflammation. 2011;8:146.
   PubMed Web of Science ®Google Scholar
• Hauser SL, Waubant E, Arnold DL, et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med. 2008;358:676–688.
   PubMed Web of Science ®Google Scholar
• Genberg H, Hansson A, Wernerson A, et al. Pharmacodynamics of rituximab in kidney transplantation. Transplantation. 2007;84:S33–S36.
   PubMed Web of Science ®Google Scholar
• Li L, Liu J, Delohery T, et al. The effects of teriflunomide on lymphocyte subpopulations in human peripheral blood mononuclear cells in vitro. J Neuroimmunol. 2013;265:82–90.
   PubMed Web of Science ®Google Scholar
• Wiendl H, Gross C, Lindner M, et al. TERI-DYNAMIC: exploring the impact of teriflunomide on immune cell population size, receptor repertoire, and function in patients with RRMS (P5.282). Neurology. 2015;86(16 Suppl.).
   Google Scholar
• Ochoa-Repáraz J, Colpitts SL, Kircher C, et al. Induction of gut regulatory CD39 T cells by teriflunomide protects against EAE. Neurol Neuroimmunol Neuroinflamm. 2016;3:e291.
   PubMed Web of Science ®Google Scholar
• Zeyda M, Poglitsch M, Geyeregger R, et al. Disruption of the interaction of T cells with antigen-presenting cells by the active leflunomide metabolite teriflunomide: involvement of impaired integrin activation and immunologic synapse formation. Arthritis Rheum. 2005;52:2730–2739.
   PubMed Web of Science ®Google Scholar
• Edling A, Woodworth L, Agrawal R, et al. Teriflunomide impacts primary microglia and astrocyte functions in vitro. Neurology. 2017;88(16 Suppl.).
   Google Scholar